Access Bio, Others Hit Back At $1B 'Windfall' Virus Test Sui

Access Bio, Others Hit Back At $1B 'Windfall' Virus Test Suit

Access Bio Inc. and two other medical companies hit back at Intrivo Diagnostics Inc.'s latest lawsuit accusing them of reneging on a deal to make COVID-19 tests, saying on Thursday that Intrivo is seeking a "windfall judgment" of $1 billion without the facts to back up its claims.

Related Keywords

Lauren Berg , Intrivo Diagnostics Inc , Ivy Pharma Inc , Areum Bio , Access Bio Inc , Intrivo Diagnostics , Access Bio , Ivy Pharma ,

© 2025 Vimarsana